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INTRODUCTION
The multiple-organ dysfunction syndrome (MODS) is a
recently deﬁned clinical entity intended to describe the pro-
gressive functional deterioration of a variety of organ sys-
tems, which occurs after exposure to a wide spectrum of
pathologic stimuli including infection, burns, and trauma
[1]. MODS is currently understood to result from the sys-
temic inflammatory response to these stimuli, which has
escaped physiologic control [2]. This inﬂammatory response
is mediated by a complex and incompletely understood
interplay of cytokines, hemostatic factors, the complement
cascade, lymphocytes, phagocytes, vascular endothelial cells,
and probably other elements currently unrecognized [2,3].
At some point in its evolution, mediators of the inﬂammato-
ry response begin to generate systemic reactions that are
detrimental to the function of many organs, or the regula-
tors of the inﬂammatory response suppress these mediators
to the point of immune deﬁciency with resultant predisposi-
tion to infection and other adverse consequences of
“immunologic dissonance.” While the precise mechanism of
the generation of these harmful reactions is not well delin-
eated, functional derangements in vascular endothelial cells
are probably involved. MODS is responsible for the majori-
ty of deaths in the intensive care unit (ICU) patient popula-
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ABSTRACT
Many of the complications of high-dose therapy with hematopoietic stem cells are caused by or lead to the multiple-
organ dysfunction syndrome (MODS). In hematopoietic stem cell transplantation (HSCT), acquired antithrombin
III (ATIII) deficiency is independently associated with MODS to the exclusion of transplant type, preparative regi-
men, and bacteremia. In experimental settings, replacement of ATIII can ameliorate the severity of MODS that
develops in response to a variety of pathologic stimuli, suggesting that ATIII supplementation might improve the
clinical course of MODS in patients undergoing HSCT. We performed a study to determine if ATIII can improve
the morbidity of MODS in HSCT. Forty-nine patients undergoing HSCT, who developed pulmonary dysfunction
(oxygen saturation of 90%), central nervous system dysfunction (drop of 4 points in the mini-mental status
exam), or hepatic dysfunction (bilirubin 34 µmol/L [2.0 mg%], weight gain of 5% over baseline, and abdominal
pain, possibly of hepatic origin) with a concomitant ATIII activity of 84% were double-blind randomized to
receive ATIII concentrate, 70 units/kg within 24 hours of recognition of initial organ dysfunction followed by 50
units/kg 8, 16, 48, and 72 hours later, or albumin placebo. The group randomized to ATIII had a lower severity-of-
illness score (15.7  19.2 vs. 28.6  25.2, p  0.03), shorter duration of hospitalization (14.9  16.7 vs. 25.7  17.9
days, p  0.03), and lower hospital charges ($138,700  $23,500 vs. $206,400  $34,000). ATIII concentrate was
associated with improved morbidity of MODS in patients undergoing HSCT when given early in the evolution of
the syndrome.
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tion [4]. Even modest degrees of MODS correlate closely
with duration of hospitalization in patients who survive [4].
In survivors of illnesses or injuries requiring ICU care,
development of MODS significantly prolongs hospitaliza-
tion and increases costs of recovery to an average of 385,000
1996 dollars [4].
High-dose therapy and hematopoietic stem cell trans-
plantation (HSCT) is associated with a variety of complica-
tions that can result in progressive functional deterioration
of many organ systems and subsequent death. There are
similarities between the complications of transplantation
and MODS in other populations of critically ill patients.
These similarities have been used to postulate that the com-
plications seen in the two populations may be the result of
similar, if not identical, processes. One of the similarities is
an association with deﬁciencies of naturally occurring anti-
coagulants such as antithrombin III (ATIII) and protein C
[5–7]. The prognosis of MODS is proportional to the
degree of deﬁciency of these proteins [8–21]. In experimen-
tal models of MODS, generally using infection or endotoxin
as a stimulus, altering the hemostatic system to minimize
fibrin accumulation has prevented progressive organ dys-
function and mortality [22–36]. Administration of ATIII,
either before or after the inciting stimulus, can prevent the
fatal MODS that occurs in these models [29–35]. This
model has been applied to human subjects with some suc-
cess. When given to patients with bacteremia and dissemi-
nated intravascular coagulation, ATIII was associated with a
trend to lower mortality [37]. When given to patients suf-
fering multisystem trauma, ATIII use was associated with
lower plasma levels of neutrophil elastase, interleukin (IL)-
6, IL-8, and signiﬁcantly fewer days in the ICU and on ven-
tilator support [38]. In none of the human or animal trials
was any adverse effect of ATIII detected. With this back-
ground, a study was designed to test the hypothesis that
ATIII supplementation would ameliorate the clinical mani-
festations of MODS from HSCT and that such improve-
ment would lower the overall cost of the HSCT procedure.
MATERIALS AND METHODS
Patients
All patients with malignant disease who were admitted
to the University of Nebraska Medical Center for HSCT
and not committed to other confounding clinical trials were
eligible to participate, except those for whom English was
not their first language and who had not completed an
eighth grade education (to allow reliable use of the mini-
mental status examination; see below).
Informed consent and high-dose therapy regimens
The study was approved by the institutional review
board. Informed consent for organ dysfunction monitoring
and infusion of the study drug (if necessary) was obtained
before beginning the high-dose therapy regimen for HSCT.
The regimens used in this study have been previously
described [5,39,40].
Organ dysfunction
All patients were screened daily by one of two individu-
als for the development of central nervous system (CNS),
pulmonary, or hepatic dysfunction. These organ dysfunc-
tions were chosen because of previous demonstrations of
their contribution to MODS and subsequent mortality in
HSCT as well as their close correlation with ATIII levels
during HSCT [5]. For our analyses, organ dysfunction was
considered as an all or none phenomenon rather than a
spectrum of increasingly severe physiologic derangements,
an approach supported by our experience in previous
cohorts of patients undergoing HSCT [5]. Grading organ
dysfunction severity at the time of presentation on a four-
point scale of progressive severity added no value in predict-
ing subsequent organ dysfunction or mortality compared
with considering organ dysfunction and no organ dysfunc-
tion as dichotomous variables, similar to the experience
using two types of organ dysfunction deﬁnitions to predict
mortality in critically ill non–HSCT patients [41]. Organ
dysfunctions were deﬁned as follows:
1) CNS—A drop in the score of the standardized mini-
mental status examination of 4 points from the pre-chemo-
therapy score. This score represents slightly more than two
standard deviations from the mean of the differences in
test/retest scores with this tool [42]. This deﬁnition has been
shown to have a speciﬁcity of 100% for delirium in subjects
with an education level of at least the eighth grade [43].
2) Pulmonary—Finger oximetry reading of SA02 90%
on two occasions on the same day separated by at least 2
hours.
3) Hepatic—A combination of bilirubin 2.0 mg%, a
weight gain of 5% over prechemotherapy weight, and
abdominal pain of possible hepatic origin. This definition
has a high degree of concordance with histologically deﬁned
veno-occlusive disease from autopsy [44] and premortem
[45] liver tissue.
MODS
Patients with single-organ dysfunction (either pul-
monary, hepatic, or CNS) during HSCT who have a con-
comitant ATIII activity of 84% have been shown to have a
71.8% likelihood of progression to multiple-organ dysfunc-
tion in the following week [5]. Consequently, for the purpos-
es of this study, patients with single-organ dysfunction with a
concomitant ATIII activity of 84% of normal were deﬁned
as having MODS.
Randomization
Patients with MODS were randomized to receive ATIII
concentrate (ATnativ, Baxter Healthcare, Glendale, CA) or
albumin placebo (5% human albumin, Baxter Healthcare).
The ATIII concentrate was given at a dose of 70 U/kg with-
in 24 hours of organ dysfunction detection, followed by 50
U/kg 8, 16, 48, and 72 hours later. The total dose of ATIII
concentrate was 270 U/kg, similar to the dose found effec-
tive in animal models [30,31,34] and human sepsis [37].
Albumin was given in a volume equal to the calculated vol-
ume of ATIII concentrate. Based on a recovery of 1.8%/U-
kg and a half-disappearance time of 12 hours 14 days after
beginning the high-dose therapy regimen for HSCT [46],
the study dose of ATIII concentrate was estimated to pro-
vide an increment of 250% activity above pretreatment
levels after the third dose, levels similar to those achieved in
prior human studies found to be effective in shortening the
WD Haire et al.
144
duration of disseminated intravascular coagulation due to
sepsis [37]. The duration of therapy was chosen based on
previously published evidence from animal [29,30,31,33,34]
and human [37] studies, suggesting efﬁcacy with 72 hours of
therapy or less.
Previously performed multivariate analyses considering
transplant type (allogeneic, autologous bone marrow, and
autologous peripheral blood stem cell), type of preparative
regimen, presence of positive blood culture, and AT III level
have shown that only the AT III level was a consistent inde-
pendent association of organ dysfunction during transplan-
tation [5]. Because transplant type, treatment regimen (and,
by inference, disease type), and bacteremia were not inde-
pendent risk factors for organ dysfunction in this popula-
tion, no attempt to stratify for these variables was made in
this study.
With no prior experimental experience available, the
degree of change in the major outcomes of the study expect-
ed from ATIII supplementation was unknown. Consequent-
ly, accurate prediction of sample size necessary to establish a
statistically significant difference between the two groups
could not be precisely estimated. The factors ultimately gov-
erning the ﬁnal number of subjects to be accrued were the
number that would reasonably be required to show a trend
to different outcomes between the two groups, the frequency
with which organ dysfunction was seen in this single institu-
tion, and the amount of funding available to carry out the
study. The number of 25 subjects in each arm was deter-
mined before beginning the study to meet these limitations.
Randomization was accomplished using a computer-gen-
erated list of random numbers. An unblinded research phar-
macist reconstituted the requisite volume of study drug and
provided it to the ward personnel in unmarked containers.
Post-randomization monitoring
After randomization, daily monitoring for organ dys-
function continued until hospital dismissal or death. Criteria
for dismissal from the hospital were standardized before the
beginning of this trial and included neutrophil recovery of
500/mm3, absence of fever or active infection, minimum
oral intake of 1000 mL of fluid and 1000 kcal, controlled
GVHD of grade less than II, ability to ambulate, and need
for no more than one daily transfusion of red blood cells or
platelets [47]. Decision for hospital dismissal was made with-
out knowledge of study treatment allocation. The severity-
of-illness score was calculated after study completion by
summing the number of organ dysfunctions (0–3) on each
day of hospitalization from the point of randomization until
dismissal or death. Thus, for example, a patient with CNS
dysfunction on 6 days, pulmonary dysfunction on 3 days,
both CNS and pulmonary dysfunction on 4 days, and no
organ dysfunction for the remaining 7 days of hospitalization
would have a severity-of-illness score of 17. The rationale of
this approach is based on the observation that there is a
direct relationship between the number of organ dysfunc-
tions per unit time and mortality in critically ill non–HSCT
patients [48], suggesting that patients with more organ dys-
functions per unit time were at greater risk of dying than
those with fewer organ dysfunctions. Consequently, this
measurement of severity of illness encompasses more than
simply the duration of hospitalization. If the MODS or its
therapy predisposed to early death, this calculation would be
expected to be falsely indicative of a good outcome. In the
absence of a higher mortality rate, a lower severity-of-illness
score would be indicative of less severe MODS.
Statistical analysis
Data are expressed as the mean  SEM. Wilcoxon’s
rank sum test assessed the difference in duration of hospital-
ization, hospital charges, and severity-of-illness scores
between the two groups. The Fisher’s exact test was used to
look at the differences in the mortality distribution of the
study groups. A p value 0.05 was considered signiﬁcant.
RESULTS
A total of 197 patients were approached to give informed
written consent. Eight patients declined to give such con-
sent, one patient had not completed an eighth grade educa-
tion and so was disqualiﬁed, and two patients had committed
to participate in another clinical trial. The demographics,
diseases, preparative regimens, and types of HSCT per-
formed for the remaining 186 patients entered into the study
are outlined in Table 1. All 186 patients were evaluable.
Significance of the definitions of organ dysfunction and MODS
Organ dysfunction was detected in 54 patients. Of this
group, 25 died during hospitalization (mortality 46.3%). The
mortality rate was 0% in the remaining 132 patients who did
not meet our criteria for organ dysfunction (p  0.0001).
Table 1. Characteristics of the population monitored for organ dysfunction
Underlying disease
Acute lymphocytic leukemia 6
Acute myelogenous leukemia 14
Breast carcinoma 51
Chronic lymphocytic leukemia 3
Chronic myeloid leukemia 19
Hodgkin’s disease 11
Multiple myeloma 12
Lymphoma 68
Miscellaneous 2
Total 186
Transplant type
Allogeneic, related 47
Allogeneic, unrelated 7
Autologous
bone marrow 33
peripheral blood 99
Total 186
Preparative regimens
Carmustine, cytarabine, etoposide, cyclophosphamide 50
Cyclophosphamide, thiotepa 18
Cyclophosphamide, thiotepa, hydroxyurea 35
Carmustine, etoposide, cyclophosphamide 19
Busulfan, cyclophosphamide 5
Cyclophosphamide, total-body irradiation 34
Cyclophosphamide, etoposide, total-body irradiation 24
Other 1
Total 186
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MODS was diagnosed by the presence of an ATIII activ-
ity of 84% in 49 of these 54 patients. That our deﬁnition
of MODS (single-organ dysfunction with a low ATIII level)
was truly indicative of a high risk of multiple-organ dysfunc-
tion is illustrated by the observation that progression to a
second- or third-organ dysfunction occurred in 29 of these
patients (16 of the 25 patients randomized to placebo, 13 of
the 24 patients randomized to ATIII), compared with zero of
the ﬁve patients with single-organ dysfunction but without a
low ATIII level (Fisher’s exact test, p  0.017). The signiﬁ-
cance of progression from single- to multiple-organ dysfunc-
tion is evident in the observation that of the 20 MODS
patients who did not progress to second-organ dysfunction,
only three died; 10 of the 19 who progressed to second- and
all 10 of those who progressed to third-organ dysfunctions
died (Fisher’s exact test, p  0.001). This also conﬁrms the
observation in non–HSCT patients that mortality is related
to the absolute number of organ dysfunctions that occur dur-
ing HSCT. In addition to predicting mortality, MODS was a
strong indicator of in-hospital morbidity. Patients with
MODS, but dismissed from the hospital alive, had longer
(37.5  19.5 days vs. 15.7  9.6 days, p  0.0001) hospital-
izations than those who did not develop MODS.
The severity-of-illness score in the 23 randomized
patients who died was 35.3  24.4 compared with 10.7  14.5
in the patients who were dismissed alive (Wilcoxon’s rank sum
test, p  0.0003), conﬁrming that mortality was related to the
duration and the absolute number of organ dysfunctions.
Results of randomization
ATIII levels were 84% in 49 (90.7%) of the 54 patients
who developed organ dysfunction (mean ATIII level  65.1 
3.1%); these patients were randomized and received a complete
course of the study drug. One patient was randomized and
received the ﬁrst dose of the study drug based on an erroneous
laboratory report. No further study drug was given and this
patient was not included in our analysis. The mean weight of
the randomized patients was 76 kg, making the mean total dose
of ATIII concentrate 20,520 U/patient. The diagnoses and
types of HSCT procedures performed on the patients who
came to randomization are listed in Table 2. There were no
significant differences between the treatment groups with
respect to these parameters. Although all patients with MODS
during unrelated allogeneic transplants who developed organ
dysfunction were randomized to receive the placebo, analysis of
outcomes of these patients showed no difference in their severi-
ty-of-illness score, hospital length of stay, or hospital charges
compared with the related allogeneic transplant patients (sever-
ity-of-illness score, 28.2  12.8 vs. 28.7  27.1; length of hos-
pital stay, 40.0  8.0 vs. 41.7  19.7 days; and hospital charges,
$233,863  $159,448 vs. $201,140  $173,789). Consequently,
any differences between the outcomes of the ATIII and placebo
groups were not due to inordinately adverse outcomes of the
unrelated allogeneic transplant patients in the placebo group.
The pattern of clinical progression from single- through
multiple-organ dysfunction after randomization is outlined
in Table 3. Of the 24 patients randomized to ATIII, 13
(54%) progressed to other organ dysfunctions compared
with 16 (64%) of 25 patients randomized to placebo (p 
NS). In the ATIII treatment group, 12 presented with CNS
dysfunction, six of whom progressed to other organ dys-
functions; 10 presented with pulmonary dysfunction, six of
whom progressed to other organ dysfunctions; and two pre-
sented with hepatic dysfunction, one of whom progressed to
other organ dysfunctions. In the group randomized to
placebo, 10 presented with CNS dysfunction, six of whom
progressed to other organ dysfunctions; nine presented with
pulmonary dysfunction, six of whom progressed to other
organ dysfunctions; and six presented with hepatic dysfunc-
tion, four of whom progressed to other organ dysfunctions.
The outcome of therapy is summarized in Table 4. The
duration of ﬁrst-, second-, and third-organ dysfunctions tend-
ed to be shorter in patients randomized to ATIII, but differ-
ences in durations of individual organ dysfunctions did not
reach statistical signiﬁcance. However, when the clinical effect
of the aggregate of these changes was considered, patients
receiving ATIII fared better than those receiving placebo.
Patients randomized to ATIII had a lower mean severity-of-
illness score (15.7  19.2 vs. 25.7  17.9, p  0.03) and a
Table 2. Characteristics of the patients randomized to treatment with
antithrombin III or placebo
Antithrombin III Placebo
Demographics
Mean age (years) 46.1  10.3 46.0  10.5
Men 10 10
Women 14 15
Total 24 25
Transplant type
Allogeneic, related 10 11
Allogeneic, unrelated 0 4
Autologous 14 10
Total 24 25
Source of stem cells
Bone marrow 8 10
Peripheral blood 16 15
Total 24 25
Underlying disease
Acute lymphocytic leukemia 0 1
Acute myeloid leukemia 5 4
Breast carcinoma 8 4
Chronic lymphocytic leukemia 0 2
Chronic myeloid leukemia 1 4
Hodgkin’s disease 0 1
Multiple myeloma 3 3
Lymphoma 7 6
Total 24 25
Preparative regimens
Carmustine, cytarabine, etoposide, 
cyclophosphamide 4 4
Cyclophosphamide, thiotepa 3 1
Cyclophosphamide, thiotepa, 
hydroxyurea 4 3
Carmustine, etoposide, 
cyclophosphamide 2 3
Busulfan, cyclophosphamide 0 1
Cyclophosphamide, total-body 
irradiation 5 5
Cyclophosphamide, etoposide, 
total-body irradiation 6 8
Total 24 25
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shorter hospitalization (14.9  16.7 vs. 25.7  17.9 days, p 
0.03) after randomization than did those randomized to place-
bo. This improvement translated to a tendency toward lower
hospital charges for the ATIII group ($138,700  $23,500 vs.
$206,400  $34,000, p  0.06). There was a lower mortality
rate in the group randomized to ATIII (39% [9/23] vs. 56%
[14/25]), but the difference did not reach statistical signiﬁ-
cance (p  0.19).
DISCUSSION
MODS has been recognized as the leading cause of
death among critically ill or injured patients [4], including
patients undergoing HSCT [5]. Our data confirmed the
unfavorable clinical course of MODS in HSCT and support-
ed the validity of the use of simple clinical measurements to
deﬁne the disorder and estimate outcomes. Patients meeting
the criteria for single-organ dysfunction had a mortality rate
approaching 50%, suggesting the presence of significant
physiologic derangement at the time of presentation, despite
the often mild deviation from normal organ function param-
eters at that time. Patients who developed no organ dysfunc-
tion by these criteria did not die. Approximately one-half of
the patients presenting with pulmonary, CNS, or hepatic
dysfunction, by our definitions, progressed to second- or
third-organ dysfunctions. An ATIII level 84% combined
with the presence of single-organ dysfunction further
improved the predictive value of progression to multiple-
organ dysfunctions. In this prospective study, the rate of
development of subsequent organ dysfunction in untreated
patients with single-organ dysfunction and a low ATIII level
was 64%, very similar to the 70.5% predictive value previ-
ously reported for this combination [5]. The development of
second- and third-organ dysfunctions was an ominous occur-
rence, with mortality reaching 100% among those who
developed CNS, hepatic, and pulmonary dysfunction. Not
only was the development of organ dysfunction an important
determinant of mortality, but the duration of organ dysfunc-
tion was also important. When the number of organ dys-
functions per day was combined with the number of days of
hospitalization, the resultant severity-of-illness score associ-
ated strongly with mortality. In addition to its relationship to
death, the severity of MODS had other clinically relevant
features. Patients who developed nonfatal MODS had
greater morbidity than did similar patients who did not
develop MODS, which likely translated into increased suf-
fering, longer hospitalization, and higher financial costs.
This was observed in both HSCT patients and in popula-
tions with other severe illnesses [4,5]. Consequently, mortali-
ty is not the only clinically relevant goal of proposed thera-
pies for this syndrome. An effective therapy should lower the
duration and cost of hospitalization and lower the severity-
of-illness score without increasing mortality. Unfortunately,
to date no specific therapy has been identified. The only
therapy available for MODS is the elimination (where possi-
ble) of its inciting stimuli and the provision of supportive
care until dysfunctional organs regain full activity.
The results of this study suggest that the clinical course
of MODS can be favorably altered with active therapy
directed at the acquired ATIII deficiency. Patients given
ATIII concentrate early in the evolution of MODS recov-
ered faster and with a lower aggregate severity of illness than
did patients given placebo. In addition to improved overall
morbidity, ATIII therapy was associated with a trend of
decreased recovery costs. In this study, the ATIII concentrate
was provided without charge; thus, the reported hospital
charges did not reﬂect the use of ATIII concentrate. Howev-
er, if one factors in the cost of the ATIII concentrate (current
average wholesale price of $.60/U), the mean cost of therapy
in this study would have been $12,312 per patient. This
compares favorably with the mean difference in hospital
charges of $67,700 per patient between those receiving
Table 3. Organ dysfunction outcomes of treatment in patients treated with
antithrombin and placeboa
Antithrombin III
CNS only 6
Pulmonary only 4
Hepatic only 1
CNS, pulmonary 5
Pulmonary, CNS 4
Hepatic, CNS, pulmonary 1
CNS, pulmonary, hepatic 1
Pulmonary, CNS, hepatic 2
Total 24
Placebo
CNS only 4
Pulmonary only 3
Hepatic only 2
CNS, pulmonary 4
Pulmonary, CNS 4
Hepatic, CNS 1
CNS, pulmonary, hepatic 2
Pulmonary, hepatic 1
Hepatic, CNS, pulmonary 3
Pulmonary, hepatic, CNS 1
Total 25
aThe type of organ dysfunction listed ﬁrst in each column is the initial organ
dysfunction. The following organ dysfunctions listed are those that occurred sub-
sequently. To simplify reporting, the second and third organ dysfunctions are
not necessarily in chronological order.
Table 4. Outcomes of treatment in patients treated with antithrombin and
placeboa
ATIII (n=24) Placebo (n=25) p
Death 9 14 0.19
Duration (days)
1st Organ dysfunction 3.5 (1.0, 63.0) 8 (0, 66.0) 0.37
2nd Organ dysfunction 5.0 (1.0, 56.0) 18.5 (1.0, 50.0) 0.15
3rd Organ dysfunction 16.0 (1.0, 34.0) 28.5 (8.0, 51.0) 0.24
Severity-of-illness score 5.5 (1.0, 77.0) 27.0 (3.0, 66.0) 0.03
Hospital length of stay
(days post-randomization) 7.5 (1.0, 62.0) 21.0 (3.0, 66.0) 0.03
Hospital charges
(thousands of dollars) 96.1 (35.0, 46.5) 118.0 (51.0, 630.3) 0.06
aResults are reported as medians, with minimum and maximum values in
parentheses.
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ATIII and those receiving placebo. Because ATIII therapy
decreased morbidity of organ dysfunction and because organ
dysfunction often leads to death, ATIII therapy might also
improve the mortality of HSCT. The mortality rate was
lower in the ATIII-treated group, but the difference was not
statistically signiﬁcant (p  0.19), although the study was not
designed to test this hypothesis. Data suggest that the evalu-
ation of the effect of ATIII on MODS mortality requires a
study randomizing 200–250 patients between active therapy
and placebo. Because 25% of all transplant patients devel-
op complications leading to MODS, such a study would
require a population of 1000 transplant patients. And
because 20,000 transplants are performed annually in the
United States, this type of study seems feasible.
In our study, treatment with ATIII resulted in a lower
frequency of progression from single- to multiple-organ dys-
function (54% progression in the ATIII group vs. 64% in the
placebo group) and a shorter duration of ﬁrst-, second-, and
third-organ dysfunctions. However, none of these differ-
ences reached statistical signiﬁcance. The aggregate severity
of all organ dysfunctions, as attested to by the severity-of-ill-
ness scores, was signiﬁcantly improved with the use of ATIII,
suggesting that individual organ dysfunctions were affected
by this intervention as well. Perhaps, as with mortality con-
siderations, the lack of statistically significant differences
might be related to the small sample size used in this study. It
is also reasonable to assume that organ dysfunctions detect-
ed, according to the deﬁnitions used in this study, were pres-
ent several days before their diagnosis, but that our tools
were too crude to detect them. Further research into meth-
ods of detecting clinically signiﬁcant organ dysfunction may
allow earlier intervention, possibly with better clinical out-
comes, including improvement in frequency of progression
from single- to multiple-organ dysfunction and duration of
single-organ dysfunction. Additionally, higher doses of ATIII
concentrate, dosing the concentrate to achieve a threshold
level of plasma activity, or longer duration of ATIII supple-
mentation may further improve outcomes. These issues
should be addressed in subsequent clinical trials.
The possibility of other explanations for the better out-
comes observed in the ATIII-treated group should be care-
fully considered. All unrelated allogeneic transplant patients
treated in this study were randomized to receive placebo.
However, the outcomes of these patients were similar to
those undergoing related allogeneic transplantation, suggest-
ing that inordinately worse outcomes in the unrelated allo-
geneic transplant patients is unlikely to explain the differ-
ences in outcomes between the ATIII and placebo groups.
The absolute numbers of autologous transplant patients was
higher in the group randomized to ATIII, while the number
of allogeneic transplant patients was higher in the group ran-
domized to placebo. This imbalance may account for some of
the differences between the outcomes of the two groups.
Data are insufficient to prove or disprove this hypothesis.
However, previous analyses have shown that while the fre-
quency and type of organ dysfunction varies with type of
transplant (allogeneic, autologous bone marrow, autologous
peripheral stem cell), treatment regimen, and disease type,
these are not independent risk factors for development of
organ dysfunction during transplantation [5]. These analyses
have shown the only consistent independent associate of
organ dysfunction is the ATIII level during the transplant
course. This is consistent with the hypothesis that the
inﬂammatory response is responsible for the generation of
much of the organ dysfunction seen during transplantation,
that ATIII is actively involved in the pathogenesis of this
response, that the ATIII level is a marker of the severity of
the inflammatory response, and that, while certain trans-
plant-speciﬁc variables (type of transplant or preparative reg-
imen) result in higher frequencies of complications, they do
so by inducing a more robust inﬂammatory response. This
suggests that differences between treatment and control arms
in the areas of transplant type, treatment regimen, and bac-
teremia might not be relevant to differences in outcomes,
except insofar as they induce a stronger inflammatory
response as manifested by lower ATIII values.  Potential con-
tributions of these variable outcomes should be considered in
any future trial of ATIII or other proposed therapy of
MODS during HSCT by limiting studies to patients with
transplant-speciﬁc variables associated with a high likelihood
of inﬂammation-associated organ dysfunctions.
The mechanism of action of ATIII concentrate is
unknown. Serine proteases are activated during the adminis-
tration of chemotherapy [49–51] and the genesis of the
inﬂammatory reaction [6–7]. The serine protease thrombin
can convert ﬁbrinogen to ﬁbrin monomer, levels of which
predict development and fatal outcome of MODS in
non–HSCT patients [52]. Additionally, thrombin has effects
on vascular endothelial cells that are of major importance in
the inﬂammatory process [53]. Thrombin causes these cells
to secrete plasminogen activator inhibitor-1 [54], an
inhibitor of fibrinolysis found in high concentrations in
patients with hepatic dysfunction during HSCT [55].
Thrombin also induces the expression of P-selectin, facilitat-
ing polymorphonuclear leukocyte adhesion to endothelial
cells and their subsequent degranulation [56,57]. Neutrophil
degranulation releases elastase and proteinase 3, serine pro-
teases that can mediate endothelial cell death by apoptosis
[58] when they become procoagulant [59] and cause further
activation of coagulation in a potentially self-propagating
manner. Thrombin stimulates production of transforming
growth factor beta [60], a predictor of pulmonary and hepat-
ic dysfunction in HSCT patients [61]. 
When activated, another serine protease, factor XII,
can generate bradykinin by activating prekallikrein and its
subsequent cleavage of high-molecular-weight kininogen
[62]. Bradykinin can produce many of the observed cellular
and physiologic effects associated with inflammation [63],
including increases in vascular permeability (part of the
clinical syndrome of hepatic veno-occlusive disease)
[43,44]. In addition to generation of bradykinin, plasma
kallikrein can induce a variety of other inflammatory reac-
tions that can lead to organ dysfunction. Specific inhibition
of plasma kallikrein can prevent inflammation-induced
pulmonary dysfunction in experimental settings [64]. Fac-
tor XII can also activate the complement cascade via the
classical pathway, generating biologically active substances
that are involved in the inflammatory reaction [62].
Inhibiting complement activation can prevent inflamma-
tion-induced pulmonary dysfunction in experimental
inflammation [65]. ATIII as an inhibitor of serine proteases
could be active at these and other interfaces of the coagula-
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tion and inﬂammatory systems, especially if present in supra-
physiologic levels, and could favorably alter their contribu-
tion to the intensity of the systemic inﬂammatory response as
one of its mechanisms of action. ATIII may also alter
cytokine expression during inﬂammation through unknown
mechanisms. When given to patients after multisystem trau-
ma, ATIII resulted in lower levels of IL-6 and IL-8 [38].
The notion that modulators of the coagulation cascade
can favorably affect the outcomes of inﬂammation is not lim-
ited to ATIII. In experimental settings, outcomes of inﬂam-
mation due to sepsis or trauma can be improved by modula-
tion of the hemostatic system by protein C [11,24], throm-
bomodulin [23], heparin [26], inhibitors of tissue factor [22],
and recombinant tissue plasminogen activator [27,28]. Simi-
lar alterations in the hemostatic system using heparin or
recombinant tissue plasminogen activator have been report-
ed to be helpful in preventing and treating hepatic veno-
occlusive disease, one of the manifestations of MODS during
HSCT [66–70]. The link between the coagulation and
inﬂammatory systems may prove to be an important focus of
therapy in HSCT and other disease processes. Perhaps fur-
ther study will open the door to ways of providing patients
with MODS more than nonspecific supportive therapy to
prevent subsequent complications and death.
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